Your browser doesn't support javascript.
loading
Estimation of the in vivo neutralization potency of eCD4Ig and conditions for AAV-mediated production for SHIV long-term remission.
Goyal, Ashish; Gardner, Matthew; Mayer, Bryan T; Jerome, Keith R; Farzan, Michael; Schiffer, Joshua T; Cardozo-Ojeda, E Fabian.
Afiliação
  • Goyal A; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Gardner M; Department of Medicine, Emory University, Atlanta, GA, USA.
  • Mayer BT; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Jerome KR; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Farzan M; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
  • Schiffer JT; Department of Immunology and Microbiology, Scripps Research Institute, Florida Campus, Jupiter, FL, USA.
  • Cardozo-Ojeda EF; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Sci Adv ; 8(2): eabj5666, 2022 Jan 14.
Article em En | MEDLINE | ID: mdl-35020436
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article